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 Smith, Sanchez-Laorden, and colleagues found that macrophage-derived 
TNFα was required for BRAFV600E-positive melanoma cell survival and pro-
tected these cells from MEK inhibitor (MEKi)–induced cell death via NFκB-
dependent upregulation of microphthalmia-associated transcription 
factor (MITF). MEK/BRAF inhibitor treatment increased tumor-associated 
macrophage recruitment and TNFα and MITF expression in BRAF-mutant 
melanomas. Intriguingly, dual treatment with IκB kinase inhibitors (IKKi) and MEKi 
suppressed both macrophage-derived TNFα expression and MITF expression in 
melanoma cells and resulted in enhanced inhibition of tumor growth in mice. These 
findings highlight the role of the immune microenvironment in MAPK inhibitor 
 resistance and suggest that IKKi therapy may improve the efficacy of MAPK pathway 
inhibitors by preventing TNFα-mediated resistance. For details, please see the 
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